<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DDB07FE7-2ED9-4228-8034-04699A414E04"><gtr:id>DDB07FE7-2ED9-4228-8034-04699A414E04</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Noble</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/836A9506-D05E-47ED-B9F0-7E1F04958C4C"><gtr:id>836A9506-D05E-47ED-B9F0-7E1F04958C4C</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Endicott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F6933D01-2737-4AF0-A356-43FC081E65B7"><gtr:id>F6933D01-2737-4AF0-A356-43FC081E65B7</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400957"><gtr:id>B9E50E9D-9914-49ED-BFB3-DDA3B1581B42</gtr:id><gtr:title>Structural studies on assemblies that regulate the cell cycle</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400957</gtr:grantReference><gtr:abstractText>In the past treatments for cancer have evolved by chance, trial and error and scientific intuition. More recently understanding a particular defect that leads to disease has led to new medicines directed towards a particular target that are proving most effective (e.g. the drugs Gleevec, Iressa and Herceptin for cancer treatment). The growth and division of cells is strictly controlled at the molecular level by a series of enzymes that include the cyclin dependent protein kinases (CDKs). These enzymes are switched off and on in an orderly sequence to ensure that cell division starts and stops at the required time. Our work, using the technique of X-ray crystallography, allows us to see these molecules and by understanding their form and shape at the molecular level we gain insights into how they function. In cancer cells genes whose products directly or indirectly control CDK function are frequently damaged thereby explaining the uncontrolled growth of tumours. Deregulation of one of the control molecules, cyclin E, leads to uncontrolled cell proliferation. Our structural studies will allow us to understand the role of this molecule in the cell cycle. This knowledge will assist in the development of new medicines by allowing scientists to predict what medicines are likely to work and which ones will not.
 Many of the processes in the cell cycle are controlled by the addition of a single phosphate group to another molecule. This small modification results in switching on or switching off of cellular activities. Three of the molecular complexes that we are studying (CDK2/cyclin E, CDK7/cyclin H/Mat1/ and polo-like kinase) catalyse this chemical modification of phosphorylation. Our structural studies will allow us to understand how out of the thousands of proteins in the cell the right molecule is selected and how this can go wrong in the diseased state. Another chemical modification important in the control of cell growth is the addition of the small molecule ubiquitin to a target molecule. This signals that the target is to be destroyed by a large molecular complex known as the proteasome. Our work seeks to understand how ubiquitin is attached to the target and how the target is then brought to the proteasome by carrier molecules that recognise both the ubiquitin and the proteasome. Cellular function is all about recognition between molecules. By seeing the molecules we can help understand cell function.</gtr:abstractText><gtr:technicalSummary>The cell division cycle integrates a variety of signal transduction pathways to ensure orderly cell cycle progression. The programme grant describes structural and other biochemical characterisation studies on a series of macromolecular assemblies that are important in cell cycle regulation. Cyclins are key components of the cell cycle machinery that bind, activate and provide substrate specificity for their associated cyclin dependent protein kinases (CDKs). We have recently determined the crystal structure of CDK2/cyclin E. In future work we shall explore substrate specificity in comparison with CDK2/cyclin A and seek to understand the role of cyclin E when over-expressed in cancer. Each of the CDKs involved in the regulation of the cell cycle is controlled by phosphorylation by another CDK, CDK7, a kinase that also has an essential role in transcription. Building on our recently determined crystal structure of CDK7, we plan to determine the structure of the active CDK7/cyclin H/Mat1 complex and to understand modulation of enzyme properties by other factors such as U1 snRNA. Polo-like kinase (Plk1) controls events at the G2/M transition of the cell cycle. The polo-box domain (PBD) regulates localisation of Plk1 to different structures. Following our crystal structure determination of the PBD with a cognate phospho-peptide we seek to determine the structure of the kinase domain and its regulation by the PBD.
 Proteasomal destruction of CDK inhibitors (CKIs) results in the activation of CDK activity that promotes cell cycle progression. The pathway requires specific molecular recognition of two post-translational events: phosphorylation and ubiquitination. Destruction of the inhibitor p27Kip1 is signalled by phosphorylation on Thr187 by pCDK2/cyclin A, which subsequently remains associated with the phosphorylated CKI to present it to the ubiquitinating E2/E3 complex CDC34/SCFSkp2 (Skp1/cullin/F-box/Skp2) complex. The interaction also requires an accessory factor Cks1. We shall develop protocols for the reconstitution of protein ubiquitination in vitro using the purified components that have been established by us and explore the structural relationships of the proteins in the multi protein complex. Once ubiquitinated, proteins may be targeted to the proteasome through mediator proteins that contain both a ubiquitin-like (UBL) domain that recognises specific proteasomal subunits and a ubiquitin-associating domain (UBA) domain that binds poly-ubiquitinated chains. Following our structure determinations of UBL and UBA domains from yeast mediator proteins, we shall study the structural recognition properties with polyubiquitin and selected fragments of the relevant proteasomal subunits.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>406546</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>The role of cyclins in CDK activation</gtr:description><gtr:id>73AF4CF5-1A63-4F57-B131-C5AC7CCEF3D0</gtr:id><gtr:impact>Several publications where input is acknowledged</gtr:impact><gtr:outcomeId>C2BE43B7B3E-1</gtr:outcomeId><gtr:partnerContribution>Discussions on the roles of cyclins in CDK activation</gtr:partnerContribution><gtr:piContribution>Discussion on the roles of cyclins. We contributed structural studies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Bis-substrates for mechanistic protein kinase studies</gtr:description><gtr:id>EBF889B2-7E9E-40C0-B5DD-259C835F2AF5</gtr:id><gtr:impact>joint publications listed in section 2 Cheng et al 2006</gtr:impact><gtr:outcomeId>1BFCF32C5AB-1</gtr:outcomeId><gtr:partnerContribution>Synthesis of new materials</gtr:partnerContribution><gtr:piContribution>Our collaboratoor provided us with novel materials for CDK mechanistic studies. We performed kinetic and structural studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3C70CB97-1527-4709-BEE2-3327450E9F70</gtr:id><gtr:title>The regulation of protein phosphorylation.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03d91e5664d851cbb6cad44dd55d10e6"><gtr:id>03d91e5664d851cbb6cad44dd55d10e6</gtr:id><gtr:otherNames>Johnson LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>53B72A93241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70DFE393-1024-4202-8DA3-9D80D9A24E61</gtr:id><gtr:title>Protein kinase inhibitors: contributions from structure to clinical compounds.</gtr:title><gtr:parentPublicationTitle>Quarterly reviews of biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03d91e5664d851cbb6cad44dd55d10e6"><gtr:id>03d91e5664d851cbb6cad44dd55d10e6</gtr:id><gtr:otherNames>Johnson LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-5835</gtr:issn><gtr:outcomeId>CC6D992D7DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>984DDB20-86E2-4CCA-988D-CF6FE5CCD189</gtr:id><gtr:title>The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f8e48a2e79aa7248cba2f4f3f00586"><gtr:id>79f8e48a2e79aa7248cba2f4f3f00586</gtr:id><gtr:otherNames>Baumli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>A956A10040A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1564400D-9C1C-4550-A3D3-7CA0E1E8FD36</gtr:id><gtr:title>Cyclin B and cyclin A confer different substrate recognition properties on CDK2.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cc8aa5474da27ea8392e2321066819c"><gtr:id>0cc8aa5474da27ea8392e2321066819c</gtr:id><gtr:otherNames>Brown NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>2C15A332B03</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA54CFA-E984-4E4B-A685-696974886504</gtr:id><gtr:title>Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d740d151e7eb65a46921599d90ef279"><gtr:id>3d740d151e7eb65a46921599d90ef279</gtr:id><gtr:otherNames>Johnson TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>D6E8AA220FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEB47264-CC3D-47A3-B349-FC9EAE87037B</gtr:id><gtr:title>The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d951a1760da16fb54fde40fe2ef2679"><gtr:id>1d951a1760da16fb54fde40fe2ef2679</gtr:id><gtr:otherNames>Cheng KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E2E6AAD3E94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCB4CF4B-7685-4C5C-9A05-4EB487557712</gtr:id><gtr:title>Recognition of Cdk2 by Cdk7.</gtr:title><gtr:parentPublicationTitle>Proteins</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4d214970d8de81f6e26b04c3668fcf7"><gtr:id>b4d214970d8de81f6e26b04c3668fcf7</gtr:id><gtr:otherNames>Lolli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-3585</gtr:issn><gtr:outcomeId>148FD353245</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400957</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>